Evaxion Biotech AS (NASDAQ:EVAX) entered into a transformational partnership with MSD in September 2024, which is tracking well towards potential option exercise in the second half of 2025.

Evaxion (NASDAQ:EVAX) is a clinical stage company that is making AI useful in the current environment by using the technology to develop new cancer-fighting vaccines. The company notes that it has ...

Good day, and thank you for standing by. Welcome to the Evaxion Biotech Business Update Full Year 2024 Conference Call and Webcast. At this time, all participants will be in listen-only mode ...

Shares of NASDAQ EVAX opened at $1.69 on Wednesday. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. The business’s 50 day moving average is $2. ...

Evaxion Biotech EVAX is preparing to release its quarterly earnings on Tuesday, 2025-04-01. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

EVAXION BIOTECH ($EVAX) is expected to release its quarterly earnings data on Tuesday, March 25th after market close, per Finnhub. Analysts are expecting revenue of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Short interest in Evaxion Biotech AS (NASDAQ:EVAX) decreased during the last reporting period, falling from 86.69K to 22.40K. This put 0.47% of the company's publicly available shares short.